Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude de phase 1/2 du BHB810 dans l'adénocarcinome gastrique avancé et de la jonction œsogastrique

19 octobre 2026 mis à jour par: BigHat Biosciences, Inc.

Phase 1/2, ouverte, multicentrique, d'escalade de dose et d'expansion de l'étude du BHB810 chez des participants atteints d'adénocarcinome gastrique avancé et de la jonction gastro-œsophagienne

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

164

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Duarte, California, États-Unis, 91010
        • Recrutement
        • City of Hope Duarte
        • Chercheur principal:
          • Dani Castillo, MD
        • Contact:
          • Jalene Tangen
          • Numéro de téléphone: 833-917-5715
          • E-mail: jtangen@coh.org
      • Santa Monica, California, États-Unis, 90404
        • Pas encore de recrutement
        • University of California at Los Angeles
        • Chercheur principal:
          • Zev Wainberg, MD
        • Contact:
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Recrutement
        • NEXT Virginia
        • Chercheur principal:
          • Alexander Spira, MD
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.

  • Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.

    • Participants in Phase 1 Backfill Cohorts & Phase 2 must be CDH17-positive by central testing.
    • Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
  • At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)

  • Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.

  • Adequate organ and marrow function as defined in the protocol

Exclusion Criteria:

  • Prior cancer treatment as follows, relative to the first planned dose of trial intervention:

    • Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
    • Monoclonal antibody-based therapy (including ADCs) within 4 weeks
    • Immune checkpoint inhibitors within 4 weeks
    • Wide-field radiation therapy (>30% marrow-bearing bones) within 4 weeks or < 2 weeks of focal palliative radiation to nontarget lesions
  • Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)

  • Known hypersensitivity or allergic reaction to BHB810 or it's excipients

  • Left ventricular ejection fraction <50% or history of congestive heart failure Class III/IV

  • QTc interval > 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc

  • Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant

  • Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.

  • Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention

  • Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dose Escalation and Backfill Cohorts

Dose escalation and backfill cohorts

Every 2 weeks IV administration

Expérimental: Recommended Phase 2 Dose Level 1 (RP2D1)

Dose level 1 of 2 prospective recommended phase 2 dose levels

Every 2 weeks IV administration

Expérimental: Recommended Phase 2 Dose Level 2 (RP2D2)

Dose level 2 of 2 prospective recommended phase 2 dose levels

Every 2 weeks IV administration

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v6.0)
Délai: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months

Investigate the safety and tolerability of BHB810 by evaluation of AEs, SAEs, DLTs, and clinically significant changes safety assessments, like lab tests, vital signs, and other safety assessments

Phase 1 (Dose Escalation & Backfill Cohorts) and Phase 2 (Dose Optimization)

DLTs apply to Phase 1 Dose Escalation Cohorts only.

Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
Incidence of participants who have a dose modification of BHB810 due to toxicity
Délai: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months

Investigate the safety and tolerability of BHB810 by assessment of dose modifications due to toxicity

Phase 1 (Dose Escalation & Backfill Cohorts)

Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
Overall Response Rate (ORR)
Délai: Screening through End of Treatment, an average of 6 months

Identify the recommended Phase 2 dose (RP2D) by comparing 2 doses of BHB810 by evaluating the ORR of participants according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Phase 2 (Dose Optimization)

Screening through End of Treatment, an average of 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Clinical Benefit Rate (CBR)
Délai: Screening through End of Treatment, an average of 6 months

Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1

Number of participants who achieve stable disease (SD) for at least 6 months, or PR or CR for any duration

Phase 1 (Dose Escalation & Backfill Cohorts)

Screening through End of Treatment, an average of 6 months
Duration of Response (DOR)
Délai: Screening through End of Treatment or last scan, an average of 6 months

Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1

Time from PR or CR to disease progression

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

Screening through End of Treatment or last scan, an average of 6 months
Progression Free Survival (PFS)
Délai: Screening through End of Treatment, an average of 6 months

Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1

Time from first dose to first documented date of progression per RECIST v1.1

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

Screening through End of Treatment, an average of 6 months
Overall Survival (OS)
Délai: Screening through End of Study, an average of 10 months

Investigate preliminary antitumor activity of BHB810

Time from first dose to death from any cause

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

Screening through End of Study, an average of 10 months
Pharmacokinetics: Area under the concentration-time curve (AUC)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Area under the concentration-time curve from zero to the end of a dosing interval at steady-state (AUC0-tau)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Maximum concentration of BHB810 (Cmax) Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Time to reach maximum drug concentration of BHB810 (Tmax)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Area under the concentration-time curve from zero to infinity (AUC0-inf)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Terminal elimination half-life (t1/2)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Volume of drug distribution during terminal phase (Vz)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Total body clearance of the drug (CL)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Pharmacokinetics: Area under the concentration-time curve from zero to last measurable concentration sample time (AUC0-last)
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the PK profile of BHB810 in blood samples

Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
Incidence of antidrug antibodies (ADAs) in blood before and after BHB810 administration
Délai: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

To characterize the ADAs and PK profile of BHB810 in blood samples

Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)

At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 juillet 2026

Achèvement primaire (Estimé)

1 décembre 2028

Achèvement de l'étude (Estimé)

1 décembre 2028

Dates d'inscription aux études

Première soumission

1 avril 2026

Première soumission répondant aux critères de contrôle qualité

7 avril 2026

Première publication (Réel)

14 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

19 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner